Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$18.51 +0.2%	$19.68	$10.21 ▼ $25.67	$4.41B	0.43	3.68 million shs	1.95 million shs
AXLA Axcella Health	$0.40	$0.84	$0.34 ▼ $41.25	$1.18M	0.46	267,009 shs	6,782 shs
FENC Adherex Technologies	$8.78 -2.9%	$7.83	$3.96 ▼ $9.29	$249.51M	0.39	92,760 shs	109,351 shs
GMDA Gamida Cell		$0.17	$0.03 ▼ $2.51	$5.04M	0.93	9.20 million shs	23.04 million shs
INMB INmune Bio	$2.31 +3.6%	$6.33	$1.89 ▼ $11.64	$52.60M	1.34	816,797 shs	1.41 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+0.71%	+0.96%	-11.46%	-4.79%	+53.92%
AXLA Axcella Health	0.00%	0.00%	0.00%	0.00%	0.00%
FENC Adherex Technologies	+1.69%	+4.09%	+8.78%	+80.44%	+50.67%
GMDA Gamida Cell	0.00%	0.00%	0.00%	0.00%	0.00%
INMB INmune Bio	-5.51%	-14.40%	-71.70%	-69.78%	-73.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.9697 of 5 stars	3.7	1.0	0.0	0.0	3.1	2.5	3.1
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	2.2528 of 5 stars	3.6	1.0	0.0	0.0	2.0	3.3	0.0
GMDA Gamida Cell	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	2.0598 of 5 stars	3.3	1.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	49.47% Upside
AXLA Axcella Health	0.00	N/A	N/A	N/A
FENC Adherex Technologies	3.25	Buy	$13.00	48.06% Upside
GMDA Gamida Cell	0.00	N/A	N/A	N/A
INMB INmune Bio	2.57	Moderate Buy	$18.40	696.54% Upside

Current Analyst Ratings Breakdown

Latest ADMA, GMDA, AXLA, INMB, and FENC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/14/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.36	$0.54 per share	34.12	$1.48 per share	12.51
AXLA Axcella Health	N/A	N/A	N/A	N/A	$1.42 per share	N/A
FENC Adherex Technologies	$47.54M	5.10	$0.03 per share	279.91	($0.21) per share	-41.81
GMDA Gamida Cell	$1.78M	0.00	N/A	N/A	($0.02) per share	0.00
INMB INmune Bio	$10K	5,446.98	N/A	N/A	$1.45 per share	1.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	32.98	26.83	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
AXLA Axcella Health	-$81.19M	-$19.25	N/A	∞	N/A	N/A	N/A	-259.91%	N/A
FENC Adherex Technologies	-$440K	-$0.51	0.00	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
GMDA Gamida Cell	-$63M	-$0.63	N/A	N/A	N/A	N/A	N/A	-57.59%	N/A
INMB INmune Bio	-$42.08M	-$1.93	0.00	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)

Latest ADMA, GMDA, AXLA, INMB, and FENC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
GMDA Gamida Cell	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
AXLA Axcella Health	N/A	0.80	0.80
FENC Adherex Technologies	N/A	5.13	4.97
GMDA Gamida Cell	213.14	2.16	2.09
INMB INmune Bio	N/A	2.64	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AXLA Axcella Health	65.07%
FENC Adherex Technologies	55.51%
GMDA Gamida Cell	50.34%
INMB INmune Bio	12.72%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
AXLA Axcella Health	2.20%
FENC Adherex Technologies	11.76%
GMDA Gamida Cell	3.40%
INMB INmune Bio	35.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
AXLA Axcella Health	11	2.95 million	2.88 million	Optionable
FENC Adherex Technologies	10	27.60 million	24.35 million	Optionable
GMDA Gamida Cell	143	154.05 million	143.70 million	Optionable
INMB INmune Bio	10	23.58 million	15.17 million	Optionable

ADMA, GMDA, AXLA, INMB, and FENC Headlines

Recent News About These Companies

INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's

July 4, 2025 | seekingalpha.com

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

July 4, 2025 | benzinga.com

INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average Target Price from Analysts

July 4, 2025 | americanbankingnews.com

INmune Bio: Hold Rating Based On Path Forward Of XPro In Subset Of AD Patients

July 3, 2025 | seekingalpha.com

BTIG Research Reiterates "Neutral" Rating for INmune Bio (NASDAQ:INMB)

July 3, 2025 | americanbankingnews.com

INmune Bio (NASDAQ:INMB) Earns "Sector Underperform" Rating from Scotiabank

July 3, 2025 | americanbankingnews.com

INmune Bio (NASDAQ:INMB) Lowered to "Hold" Rating by Raymond James Financial

July 3, 2025 | americanbankingnews.com

Maxim Group Cuts INmune Bio (NASDAQ:INMB) Price Target to $8.00

July 2, 2025 | marketbeat.com

INmune slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss

July 2, 2025 | au.finance.yahoo.com

Scotiabank Downgrades INmune Bio (INMB)

July 2, 2025 | msn.com

INmune Bio: What's Left For Investors

July 2, 2025 | seekingalpha.com

INmune Bio (NASDAQ:INMB) Rating Lowered to Hold at Raymond James Financial

July 2, 2025 | marketbeat.com

Alzheimer's trial misses goal, but subgroup result offers path forward

July 1, 2025 | thepharmaletter.comT

INmune Bio (NASDAQ:INMB) Lowered to "Neutral" Rating by BTIG Research

July 1, 2025 | marketbeat.com

INmune Bio (NASDAQ:INMB) Lowered to Sector Underperform Rating by Scotiabank

July 1, 2025 | marketbeat.com

Xpro phase II miss as Inmune’s Mindful tunes in to AD subgroup

July 1, 2025 | bioworld.comB

INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results

July 1, 2025 | finance.yahoo.com

INmune Bio fails to meet main goal in Alzheimer's treatment study

July 1, 2025 | msn.com

INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble

July 1, 2025 | finance.yahoo.com

INmune Bio slumps on midstage fail for Alzheimer's drug

July 1, 2025 | pharmaphorum.comP

INmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug Trial

July 1, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA, GMDA, AXLA, INMB, and FENC Company Descriptions

ADMA Biologics NASDAQ:ADMA

$18.51 +0.04 (+0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$18.36 -0.16 (-0.84%)

As of 07:52 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Axcella Health NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Adherex Technologies NASDAQ:FENC

$8.78 -0.26 (-2.88%)

Closing price 04:00 PM Eastern

Extended Trading

$8.76 -0.01 (-0.17%)

As of 04:04 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Gamida Cell NASDAQ:GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

INmune Bio NASDAQ:INMB

$2.31 +0.08 (+3.59%)

Closing price 04:00 PM Eastern

Extended Trading

$2.32 +0.01 (+0.43%)

As of 07:58 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time